Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WVE-006 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| WVE-006 (Dose 1) | EXPERIMENTAL | - |
| WVE-006 (Dose 2) | EXPERIMENTAL | - |
| WVE-006 (Dose 3) | EXPERIMENTAL | - |
| Single Ascending Dose (SAD): WVE-006 30 milligram (mg) or placebo | EXPERIMENTAL | - |
| SAD: WVE-006 100 mg or placebo | EXPERIMENTAL | - |
| SAD WVE-006 200 mg or placebo | EXPERIMENTAL | - |
| SAD: WVE-006 400 mg or placebo | EXPERIMENTAL | - |
| SAD: WVE-006 600 mg or placebo | EXPERIMENTAL | - |
| Multiple Dose: WVE-006 600 mg Every 2 weeks (Q2W) or placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| WVE-006 | DRUG | RNA editing oligonucleotide |
Inclusion Criteria: * Healthy as determined by the Investigator, based on a medical evaluation, or has mild to moderate AATD-induced lung disease (FEV1 ≥50%) and/or stable mild AATD-induced liver disease (≤F2 (≤10 kPa) on FibroScan. * Genetic testing confirming Pi\*ZZ. * Participant has been a non-...
WVE-006 is an investigational small molecule being developed for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition. It is designed to target the AAT protein. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
WVE-006 targets the AAT protein, which is associated with Alpha-1 Antitrypsin Deficiency. By targeting this protein, the drug aims to address the underlying cause of the condition. It is currently being studied in early-stage clinical trials.
WVE-006 is being developed by Wave Life Sciences Ltd., a biopharmaceutical company listed on the stock exchange under the ticker WVE. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Alpha-1 Antitrypsin Deficiency.
WVE-006 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received FDA approval. The drug is being studied in healthy volunteers and in patients with Alpha-1 Antitrypsin Deficiency to assess its safety, tolerability, and pharmacokinetics.
WVE-006 is being studied in two clinical trials. The first, NCT06186492, is a completed Phase 1 study in healthy participants with wild-type AAT expression. The second, NCT06405633, is an active Phase 1b/2a study in participants with Pi*ZZ AATD, a specific genotype of the condition.
WVE-006 is the drug being evaluated in the RestorAATion-1 trial, which is a Phase 1 study with the clinical trial identifier NCT06186492. This trial is designed to evaluate the safety, tolerability, and pharmacokinetics of WVE-006 in healthy participants with wild-type AAT expression.